Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 313,600 shares, a drop of 37.4% from the February 13th total of 500,700 shares. Based on an average trading volume of 3,190,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.0% of the shares of the stock are short sold.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th.
Get Our Latest Stock Analysis on CPIX
Institutional Inflows and Outflows
Cumberland Pharmaceuticals Price Performance
Shares of CPIX traded down $0.14 during mid-day trading on Monday, hitting $5.32. 12,981 shares of the company were exchanged, compared to its average volume of 858,893. The stock has a market cap of $74.25 million, a price-to-earnings ratio of -6.91 and a beta of -0.18. Cumberland Pharmaceuticals has a 1-year low of $1.04 and a 1-year high of $7.25. The company has a 50 day moving average of $4.07 and a 200-day moving average of $2.38. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.99 and a current ratio of 1.13.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last announced its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Read More
- Five stocks we like better than Cumberland Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- Occidental Petroleum: 4 Reasons to Love These Prices
- How to Calculate Return on Investment (ROI)
- Super Micro’s International Presence Makes It a Winning Stock
- What Investors Need to Know to Beat the Market
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.